AbCellera Biologics has a quick ratio of 7.75. It generally indicates good short-term financial strength.
The historical rank and industry rank for AbCellera Biologics's Quick Ratio or its related term are showing as below:
ABCL'
s Quick Ratio Range Over the Past 10 Years
Min: 1.58 Med: 7.82 Max: 16.19
Current: 7.75
During the past 6 years, AbCellera Biologics's highest Quick Ratio was 16.19. The lowest was 1.58. And the median was 7.82.
ABCL's Quick Ratio is ranked better than 73.44% of 1551
companies
in the Biotechnology industry
Industry Median: 3.53
vs ABCL: 7.75
AbCellera Biologics Quick Ratio Historical Data
The historical data trend for AbCellera Biologics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AbCellera Biologics's Quick Ratio
For the Biotechnology subindustry, AbCellera Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Quick Ratio falls into.
AbCellera Biologics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
AbCellera Biologics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (NAS:ABCL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
AbCellera Biologics Quick Ratio Related Terms
Thank you for viewing the detailed overview of AbCellera Biologics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
AbCellera Biologics (AbCellera Biologics) Business Description
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABCL has been successfully added to your 